DMK Pharmaceuticals is a specialty biopharmaceutical company based in Del Mar, CA, dedicated to developing and commercializing innovative products to address significant unmet medical needs. Their FDA-approved products, SYMJEPI epinephrine and ZIMHI naloxone, cater to emergency treatments for acute allergic reactions and opioid overdose rescue, respectively.
With a focus on neuro-based disorders, DMK Pharmaceuticals is advancing a pipeline of potential blockbuster products, including treatments for Opioid Use Disorder, benign prostatic hyperplasia, and Parkinson's disease. The company's commitment to patients drives their mission to provide solutions for change in the healthcare landscape.
Generated from the website